+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
In Vitro Lung Model Market by Model Type, Application, Cell Source, Technology, Product Type, End Users - Global Forecast to 2030- Product Image
In Vitro Lung Model Market by Model Type, Application, Cell Source, Technology, Product Type, End Users - Global Forecast to 2030- Product Image
Sale

In Vitro Lung Model Market by Model Type, Application, Cell Source, Technology, Product Type, End Users - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889471
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The In Vitro Lung Model Market grew from USD 689.38 million in 2024 to USD 812.58 million in 2025. It is expected to continue growing at a CAGR of 17.05%, reaching USD 1.77 billion by 2030.

Pioneering Advances in In Vitro Lung Modeling

The landscape of respiratory research has undergone a dramatic transformation as in vitro lung models emerge at the forefront of translational science. By replicating the complex architecture and cellular interactions of pulmonary tissue, these platforms offer unprecedented fidelity in studying disease mechanisms, screening therapeutic candidates, and evaluating toxicological responses. Their growing relevance reflects an industry-wide imperative to reduce reliance on animal testing while accelerating drug discovery and personalized treatment strategies.

This executive summary distills the critical developments, market drivers, and strategic imperatives shaping the in vitro lung model sector. Drawing on rigorous research and expert validation, it illuminates the forces redefining how academic institutions, contract research organizations, biopharma companies, and regulatory bodies approach respiratory R&D. The analysis that follows equips decision-makers with a concise yet thorough understanding of the market’s current state and its evolving potential.

Navigating the Tide of Technological and Regulatory Change

A confluence of technological innovation and shifting regulatory expectations is propelling the in vitro lung model field into a new era. Three-dimensional organoid cultures and microengineered lung-on-a-chip systems have unlocked capabilities to simulate alveolar and bronchial microenvironments with remarkable precision. Meanwhile, advances in stem cell biology and scaffold design are enabling personalized models that mirror individual patient physiology.

In parallel, regulatory agencies worldwide are advocating for alternative methods that reduce animal use and improve human relevance. Initiatives promoting data standardization and validation frameworks have accelerated adoption of complex multicellular assays. These shifts are transforming the landscape from proof-of-concept demonstrations to routine deployment in high-throughput screening, toxicology assays, and bespoke drug development pipelines.

Assessing the Weight of 2025 US Tariff Adjustments

The implementation of new tariffs in the United States effective 2025 has introduced additional cost considerations across the in vitro lung model supply chain. Increased duties on imported microfluidic components, specialized reagents, and precision instrumentation have elevated operational expenses for providers and end users alike. Many suppliers have responded by sourcing alternate domestic channels or negotiating long-term contracts to mitigate price fluctuations.

These tariff adjustments have also influenced project timelines as procurement cycles lengthen to accommodate customs processes and cost-benefit analyses. Some research entities are exploring collaborative models that pool resources and localize critical reagent preparation. Although the tariffs present challenges, they have catalyzed strategic reevaluation of sourcing strategies and reinforced the value of building resilient, diversified partnerships across the Americas, Europe, and Asia.

Unpacking Market Diversity Through Segmentation Analysis

Understanding the full breadth of opportunity within the in vitro lung model market requires a granular view of its key segments. When examining model type, the analysis spans two-dimensional cell cultures differentiated by established cell line cultures and primary cell cultures, three-dimensional organoids subdivided into alveolar organoids and bronchial organoids, advanced lung-on-a-chip platforms that integrate microfluidic flow with cellular co-cultures, and precision-cut lung slices that preserve the native tissue architecture. Each modality exhibits distinct strengths in replicating pulmonary physiology, influencing its adoption across research and development applications.

Within applications, the market encompasses in vitro assays for disease modeling that recreate pathophysiological processes, drug discovery and development workflows that streamline candidate selection and target validation, personalized medicine efforts that leverage patient-derived tissues for bespoke therapeutic strategies, and toxicity testing protocols that assess pulmonary responses to environmental and pharmaceutical agents. The rising demand for predictive, high-throughput assays has accelerated integration of these in vitro systems into core research programs.

The choice of cell source further differentiates market offerings, spanning animal-derived cells for foundational studies, immortalized cell lines for reproducibility and scalability, and human-derived cells that include both primary cells directly isolated from donors and stem cell-derived cells that offer renewable and patient-specific models. This spectrum ensures flexibility in balancing physiological relevance, experimental control, and ethical considerations.

Technological innovation underpins each model category. Microfluidics delivers either continuous flow systems that replicate circulatory dynamics or droplet-based systems optimized for miniaturized, parallelized assays. Scaffold-based cultures employ either naturally sourced matrices or synthetic scaffolds to provide three-dimensional support, while scaffold-free cultures utilize bioreactors or hanging-drop approaches to foster tissue self-organization without exogenous matrix materials.

In terms of product type, the market differentiates between sophisticated instruments such as microfluidic cartridges, imaging platforms, and bioreactors, and the consumable kits and reagents required for cellular assays. This dual structure reflects the interdependence of hardware and biochemical components in delivering reliable, reproducible results.

End users span academic and research institutes driving basic science discovery, contract research organizations offering turnkey assay services, pharmaceutical and biotechnology companies integrating in vitro lung models into preclinical pipelines, and regulatory agencies seeking to incorporate human-relevant data into safety and efficacy evaluations. Each stakeholder group leverages these platforms to meet unique objectives, from early-stage mechanistic exploration to late-stage risk assessment.

Regional Footprints Shaping Market Trajectories

Across the Americas, established research hubs in North America maintain leadership in technology development and clinical translation, supported by robust funding mechanisms and a dense network of academic-industry collaborations. Latin American centers are progressively adopting in vitro models for public health research, particularly in regions grappling with infectious respiratory diseases.

In Europe, Middle East & Africa, concerted efforts toward regulatory harmonization and ethical testing are driving uptake of advanced lung models. The European Union’s Open Science initiatives and public-private partnerships in the Middle East are accelerating access to cutting-edge platforms, while burgeoning research communities in North and Sub-Saharan Africa are laying the groundwork for localized applications in environmental health and tropical disease research.

Within Asia-Pacific, governments are championing biotechnology as a strategic priority, resulting in expanded funding for tissue engineering and microfluidics research. Major academic centers and contract research organizations in China, Japan, South Korea, and Australia are rapidly integrating in vitro lung models into multi-omics workflows and AI-powered screening, positioning the region as a key growth driver for next-generation respiratory research.

Competitive Landscape and Leading Innovators

A cohort of trailblazing companies is driving the in vitro lung model sector forward through product innovation, strategic partnerships, and geographic expansion. Leading microfluidics specialists have introduced modular lung-on-a-chip platforms compatible with existing imaging and automation systems. Meanwhile, organoid technology providers are refining protocols for reproducible alveolar and bronchial tissue assembly and scaling production of stem cell-derived sources.

Reagent suppliers have responded by developing bespoke media formulations and defined extracellular matrices tailored for pulmonary models. Contract research organizations are expanding service offerings to include integrated toxicology screening and custom model development, while select pharmaceutical companies are forging alliances with academic centers to co-develop models that de-risk late-stage candidate evaluation.

Noteworthy collaborations between instrument manufacturers and software developers are yielding AI-driven analysis pipelines, enabling high-content imaging and predictive analytics that enhance assay throughput and data richness. Concurrently, a trend toward mergers and acquisitions is consolidating capabilities across hardware, software, and consumables, setting the stage for end-to-end solutions.

Strategies for Driving Growth and Resilience

To capitalize on emerging opportunities, industry leaders should prioritize investment in modular microfluidic platforms that are interoperable with automation and imaging systems, thereby reducing integration barriers and accelerating project timelines. Equally critical is diversifying supply chains to include regional reagent manufacturers and contract developers, which can mitigate tariff-related cost pressures and ensure continuity of critical materials.

Academic partnerships remain a fertile source of novel model concepts and validation data. By co-funding translational research projects, commercial entities can gain early access to breakthrough protocols and foster brand recognition within key research communities. Proactive engagement with regulatory stakeholders will also be essential for clarifying validation requirements and expediting adoption of novel in vitro assays for safety assessment.

Expanding presence in high-growth Asia-Pacific markets through strategic alliances and local facility investments can provide access to new customer segments and skilled talent pools. Concurrently, developing integrated service packages that combine instrument leasing, reagent supply, and data analytics can create recurring revenue streams and deepen customer relationships.

Finally, embedding artificial intelligence and machine-learning capabilities into data output workflows will elevate the predictive power of in vitro lung models, enabling early detection of efficacy or toxicity signals and reducing the risk of downstream program failures.

Rigorous Research Framework Underpinning Analysis

This analysis is grounded in a rigorous research framework combining primary and secondary methodologies. An extensive literature review encompassed peer-reviewed publications, regulatory guidelines, and patent filings to map technological trajectories and validation standards. Expert interviews with leading academics, industry technologists, and regulatory advisors provided nuanced perspectives on adoption barriers and future needs.

Data triangulation ensured the integration of quantitative findings with qualitative insights, while cross-validation against publicly available financial and operational disclosures provided an additional layer of reliability. Segmentation analyses were applied to each data dimension, followed by iterative peer review to confirm coherence and relevance. The resulting report reflects a balanced synthesis of market intelligence, technical scrutiny, and strategic foresight.

Synthesis and Forward-Looking Perspective

The in vitro lung model market stands at the nexus of technological innovation, ethical imperatives, and evolving regulatory expectations. By offering human-relevant insights earlier in the discovery process, these platforms are reshaping how respiratory diseases are studied and treated. The combined pressures of cost containment and the need for predictive accuracy are accelerating adoption across academia, CROs, and industry alike.

Looking ahead, continued convergence of microengineering, stem cell biology, and data analytics will further expand model capabilities, enabling more complex immune interactions and chronic exposure scenarios. As standardization efforts mature, in vitro platforms are poised to become an integral component of safety and efficacy assessment, harmonized across international regulatory frameworks.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Model Type
    • 2D Cell Cultures
      • Cell Line Cultures
      • Primary Cell Cultures
    • 3D Organoids
      • Alveolar Organoids
      • Bronchial Organoids
    • Lung-On-A-Chip
    • Precision-Cut Lung Slices
  • Application
    • Disease Modeling
    • Drug Discovery & Development
    • Personalized Medicine
    • Toxicity Testing
  • Cell Source
    • Animal-Derived Cells
    • Cell Lines
    • Human-Derived Cells
      • Primary Cells
      • Stem Cell-Derived Cells
  • Technology
    • Microfluidics
      • Continuous Flow Systems
      • Droplet-Based Systems
    • Scaffold-Based Cultures
      • Natural Scaffolds
      • Synthetic Scaffolds
    • Scaffold-Free Cultures
      • Bioreactors
      • Hanging Drop
  • Product Type
    • Instruments
    • Kits & Reagents
  • End Users
    • Academic & Research Institutes
    • CROs
    • Pharmaceutical & Biotechnology Companies
    • Regulatory Agencies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Emulate, Inc.
  • MIMETAS B.V.
  • CN Bio Innovations Ltd.
  • Hurel Corporation
  • TissUse GmbH
  • Epithelix Sàrl
  • MatTek Life Sciences, Inc.
  • InSphero AG
  • Kirkstall Ltd
  • Stemina Biomarker Discovery, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. in Vitro Lung Model Market, by Model Type
8.1. Introduction
8.2. 2D Cell Cultures
8.2.1. Cell Line Cultures
8.2.2. Primary Cell Cultures
8.3. 3D Organoids
8.3.1. Alveolar Organoids
8.3.2. Bronchial Organoids
8.4. Lung-On-A-Chip
8.5. Precision-Cut Lung Slices
9. in Vitro Lung Model Market, by Application
9.1. Introduction
9.2. Disease Modeling
9.3. Drug Discovery & Development
9.4. Personalized Medicine
9.5. Toxicity Testing
10. in Vitro Lung Model Market, by Cell Source
10.1. Introduction
10.2. Animal-Derived Cells
10.3. Cell Lines
10.4. Human-Derived Cells
10.4.1. Primary Cells
10.4.2. Stem Cell-Derived Cells
11. in Vitro Lung Model Market, by Technology
11.1. Introduction
11.2. Microfluidics
11.2.1. Continuous Flow Systems
11.2.2. Droplet-Based Systems
11.3. Scaffold-Based Cultures
11.3.1. Natural Scaffolds
11.3.2. Synthetic Scaffolds
11.4. Scaffold-Free Cultures
11.4.1. Bioreactors
11.4.2. Hanging Drop
12. in Vitro Lung Model Market, by Product Type
12.1. Introduction
12.2. Instruments
12.3. Kits & Reagents
13. in Vitro Lung Model Market, by End Users
13.1. Introduction
13.2. Academic & Research Institutes
13.3. CROs
13.4. Pharmaceutical & Biotechnology Companies
13.5. Regulatory Agencies
14. Americas in Vitro Lung Model Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa in Vitro Lung Model Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific in Vitro Lung Model Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Emulate, Inc.
17.3.2. MIMETAS B.V.
17.3.3. CN Bio Innovations Ltd.
17.3.4. Hurel Corporation
17.3.5. TissUse GmbH
17.3.6. Epithelix Sàrl
17.3.7. MatTek Life Sciences, Inc.
17.3.8. InSphero AG
17.3.9. Kirkstall Ltd
17.3.10. Stemina Biomarker Discovery, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. IN VITRO LUNG MODEL MARKET MULTI-CURRENCY
FIGURE 2. IN VITRO LUNG MODEL MARKET MULTI-LANGUAGE
FIGURE 3. IN VITRO LUNG MODEL MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. IN VITRO LUNG MODEL MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. IN VITRO LUNG MODEL MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. IN VITRO LUNG MODEL MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES IN VITRO LUNG MODEL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 76. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 78. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 79. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 81. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 82. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 83. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 84. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 85. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 86. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. CANADA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 89. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 90. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 93. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 94. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 95. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 97. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 98. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 99. MEXICO IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 149. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 150. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 151. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 156. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 157. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 158. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 159. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 160. GERMANY IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 161. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 162. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 163. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 164. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 166. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 167. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 168. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 169. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 170. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 171. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 172. FRANCE IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 185. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 186. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 187. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 188. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 190. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 191. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 193. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 194. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 195. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 196. ITALY IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 197. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 198. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 199. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 200. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 202. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 203. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 204. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 205. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 206. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 207. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 208. SPAIN IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 245. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 246. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 247. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 248. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 250. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 251. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 252. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 253. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 254. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 255. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. DENMARK IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 269. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 270. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 271. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 272. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 274. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 275. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 276. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 277. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 278. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 279. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 280. QATAR IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 281. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 282. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 283. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 284. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 286. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 287. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 288. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 289. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 290. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 291. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. FINLAND IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. SWEDEN IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 313. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 314. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 315. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 316. NIGERIA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 317. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 318. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 319. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 320. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 322. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 323. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 324. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 325. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2030 (USD MILLION)
TABLE 326. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2030 (USD MILLION)
TABLE 327. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. EGYPT IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 329. TURKEY IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
TABLE 330. TURKEY IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2030 (USD MILLION)
TABLE 331. TURKEY IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2030 (USD MILLION)
TABLE 332. TURKEY IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 333. TURKEY IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 334. TURKEY IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2030 (USD MILLION)
TABLE 335. TURKEY IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 336. TURKEY IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2030 (USD MILLION)
TABLE 337. TURKEY IN VITR

Companies Mentioned

The companies profiled in this In Vitro Lung Model market report include:
  • Emulate, Inc.
  • MIMETAS B.V.
  • CN Bio Innovations Ltd.
  • Hurel Corporation
  • TissUse GmbH
  • Epithelix Sàrl
  • MatTek Life Sciences, Inc.
  • InSphero AG
  • Kirkstall Ltd
  • Stemina Biomarker Discovery, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 812.58 Million
Forecasted Market Value ( USD ) by 2030 $ 1770 Million
Compound Annual Growth Rate17.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

In Vitro Lung Model - Global Strategic Business Report - Product Image

In Vitro Lung Model - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
In Vitro Lung Model Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F - Product Image

In Vitro Lung Model Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
In-Vitro Lung Model Market Report 2025 - Product Image

In-Vitro Lung Model Market Report 2025

  • Report
  • 200 Pages
  • Global
From
In Vitro Lung Model Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

In Vitro Lung Model Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 87 Pages
  • Global
From
Lungs in Vitro Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Image

Lungs in Vitro Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 89 Pages
  • Global
From

About the In Vitro Lung Model Market

The In Vitro Lung Model market is a subset of the In Vitro Diagnostics (IVD) industry. It is composed of products and services used to simulate the human lung in a laboratory setting. These models are used to study the effects of drugs, toxins, and other substances on the respiratory system. They are also used to develop new treatments and therapies for respiratory diseases. In Vitro Lung Models are typically composed of a combination of cell cultures, organoids, and 3D printed scaffolds. These models are used to study the effects of drugs, toxins, and other substances on the respiratory system. They are also used to develop new treatments and therapies for respiratory diseases. The In Vitro Lung Model market is highly competitive, with many companies offering a variety of products and services. Some of the major players in the market include Thermo Fisher Scientific, Merck KGaA, PromoCell, Lonza, and Corning. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.